[go: up one dir, main page]

PE20130046A1 - Procedimiento de sintesis y forma cristalina hidrocloruro de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida asi como las composiciones farmaceuticas que la contienen - Google Patents

Procedimiento de sintesis y forma cristalina hidrocloruro de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida asi como las composiciones farmaceuticas que la contienen

Info

Publication number
PE20130046A1
PE20130046A1 PE2012000695A PE2012000695A PE20130046A1 PE 20130046 A1 PE20130046 A1 PE 20130046A1 PE 2012000695 A PE2012000695 A PE 2012000695A PE 2012000695 A PE2012000695 A PE 2012000695A PE 20130046 A1 PE20130046 A1 PE 20130046A1
Authority
PE
Peru
Prior art keywords
formula
compound
synthesis
procedure
propoxi
Prior art date
Application number
PE2012000695A
Other languages
English (en)
Inventor
Nicolas Robert
Jean-Pierre Lecouve
Loic Meunier
Matheiu Boiret
Jean-Michel Lerestif
Marina Gaillard
Philippe Letellier
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20130046A1 publication Critical patent/PE20130046A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63Esters of sulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/041,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/061,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO DE SINTESIS DEL COMPUESTO DE FORMULA (I) QUE COMPRENDE: A) HACER REACCIONAR EL COMPUESTO DE FORMULA (II) CON AMONIACO A UNA TEMPERATURA SUPERIOR A 100ºC PARA FORMAR EL COMPUESTO DE FORMULA (III); B) REDUCIR EL COMPUESTO ANTERIOR EN PRESENCIA DE H Y DE UN CATALIZADOR METALICO PARA DAR LUGAR A LA AMINA BICICLICA DE FORMULA (IV); C) EL COMPUESTO DE FORMULA (IV) SE SOMETE A: i) UNA REACCION DE ACOPLAMIENTO EN PRESENCIA DE UN CARBONATO, AMINA O UN HIDROXIDO, EN UN MEDIO POLAR CONSTITUIDO POR CETONAS, ETERES, ENTRE OTROS CON UN COMPUESTO DE FORMULA (V), DONDE Y ES -CH2-HAL, HAL ES HALOGENO, ENTRE OTROS; ii) UNA AMINACION REDUCTORA EN MEDIO ACIDO CON UN COMPUESTO DE FORMULA (V´) , DONDE R´Y R´´ SON INDEPENDIENTEMENTE ALQUILO-(C1-C6), ENTRE OTROS; O iii) UNA AMINACION REDUCTORA CON UN COMPUESTO DE FORMULA (V´´), PARA DAR LUGAR A LA BASE LIBRE DEL COMPUESTO DE FORMULA (I) QUE EN PRESENCIA DE ACIDO CLORHIDRICO FORMA EL COMPUESTO DE FORMULA (I). SE REFIERE TAMBIEN A UNA FORMA CRISTALINA CARACTERIZADA POR UN DIAGRAMA DE DIFRACCION X SOBRE POLVO QUE PRESENTA LAS LINEAS DE DIFRACCION (ANGULO DE BRAGG 2 TETHA) SIGUIENTES: 16,97º, 17,84º 18,90º, 20,32º 23,87º, 27,10º, 27,86º Y 30,34º. REFERIDO ADEMAS A UNA COMPOSICION FARMACEUTICA, SIENDO UTIL PARA EL TRATAMIENTO DE TRASTORNOS COGNITIVOS Y PSICOCOMPORTAMENTALES
PE2012000695A 2011-06-08 2012-05-22 Procedimiento de sintesis y forma cristalina hidrocloruro de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida asi como las composiciones farmaceuticas que la contienen PE20130046A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1101746A FR2976285B1 (fr) 2011-06-08 2011-06-08 Procede de synthese et forme cristalline du chlorhydrate de 4-{3-[cis-hexahydrocypenta[c]pyrrol-2(1h)-yl]propoxy}benzamide ainsi que les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
PE20130046A1 true PE20130046A1 (es) 2013-02-10

Family

ID=46172744

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000695A PE20130046A1 (es) 2011-06-08 2012-05-22 Procedimiento de sintesis y forma cristalina hidrocloruro de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida asi como las composiciones farmaceuticas que la contienen

Country Status (44)

Country Link
US (3) US8664408B2 (es)
EP (1) EP2532651B1 (es)
JP (2) JP5680022B2 (es)
KR (2) KR20120136296A (es)
CN (1) CN102816102A (es)
AP (1) AP2012006280A0 (es)
AR (1) AR086848A1 (es)
AU (1) AU2012203062B2 (es)
BR (1) BR102012013573A2 (es)
CA (1) CA2779045C (es)
CL (1) CL2012001500A1 (es)
CO (1) CO6580197A1 (es)
CR (1) CR20120274A (es)
CU (1) CU20120087A7 (es)
CY (1) CY1116739T1 (es)
DK (1) DK2532651T3 (es)
EA (1) EA022741B1 (es)
EC (1) ECSP12011941A (es)
ES (1) ES2554933T3 (es)
FR (1) FR2976285B1 (es)
GE (1) GEP20156395B (es)
GT (1) GT201200182A (es)
HR (1) HRP20151073T1 (es)
HU (1) HUE028050T2 (es)
IL (1) IL219925A0 (es)
MA (1) MA33883B1 (es)
MD (1) MD4345C1 (es)
ME (1) ME02346B (es)
MX (1) MX2012006525A (es)
NI (1) NI201200102A (es)
PE (1) PE20130046A1 (es)
PH (1) PH12012000124A1 (es)
PL (1) PL2532651T3 (es)
PT (1) PT2532651E (es)
RS (1) RS54279B1 (es)
RU (1) RU2013158817A (es)
SG (1) SG186546A1 (es)
SI (1) SI2532651T1 (es)
SV (1) SV2012004237A (es)
TN (1) TN2012000254A1 (es)
TW (1) TWI499584B (es)
UY (1) UY34110A (es)
WO (1) WO2012168657A1 (es)
ZA (1) ZA201204183B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3003466B1 (fr) 2013-03-22 2015-08-07 Servier Lab Utilisation du 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide pour le traitement des douleurs neuropathiques
CN103601666B (zh) * 2013-11-28 2015-09-02 遵义医学院 八氢环戊烷[c]吡咯的制备方法
CN104387313B (zh) * 2014-10-22 2015-12-30 滨海博大化工有限公司 一种1,2-环戊二甲酰亚胺的制备方法
KR101966221B1 (ko) * 2017-06-14 2019-04-12 최상근 유해가스 처리 장치
CN115232058A (zh) * 2022-08-01 2022-10-25 上海巽田科技股份有限公司 一种格列齐特中间体1,2-环戊二甲酰胺的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US756120A (en) * 1902-07-28 1904-03-29 Krupp Gmbh Recoil-gun with special devices for protecting the slide-tracks from dust.
NL132376C (es) * 1966-02-10
US4895840A (en) * 1987-06-10 1990-01-23 A. H. Robins Company, Incorporated N-(aryl-,aryloxy-,arylthio-arylsulfinyl-and arylsulfonyl-)alkyl-N,N'-(or n'n')alkylaminoalkyl ureas and cyanoguanidines
CN1314340A (zh) * 2000-03-21 2001-09-26 山东省医药工业研究所 环戊烷酰亚胺的制备方法
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN100424077C (zh) * 2005-06-07 2008-10-08 台州市四维化工厂 一种环戊烷1,2-二酰亚胺的制备方法
FR2937251B1 (fr) * 2008-10-16 2011-03-18 Servier Lab Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil
PA8850301A1 (es) * 2008-11-26 2010-07-27 Abbott Lab Nuevas octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio
FR2953515B1 (fr) * 2009-12-09 2011-12-23 Servier Lab Nouveaux derives du type hexahydrocyclopenta[b]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2974729B1 (fr) * 2011-05-02 2013-04-19 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
ME02346B (me) 2016-06-20
ES2554933T3 (es) 2015-12-28
RS54279B1 (sr) 2016-02-29
JP5680022B2 (ja) 2015-03-04
CL2012001500A1 (es) 2014-09-05
NZ600474A (en) 2013-12-20
FR2976285A1 (fr) 2012-12-14
CY1116739T1 (el) 2017-03-15
SV2012004237A (es) 2013-01-04
HUE028050T2 (en) 2016-11-28
AP2012006280A0 (en) 2012-06-30
MX2012006525A (es) 2013-01-09
CA2779045A1 (fr) 2012-12-08
MD4345C1 (ro) 2015-11-30
EA201200726A1 (ru) 2013-04-30
US20120316214A1 (en) 2012-12-13
PL2532651T3 (pl) 2016-01-29
AU2012203062A1 (en) 2013-01-10
PT2532651E (pt) 2015-10-15
TW201302702A (zh) 2013-01-16
CU20120087A7 (es) 2014-01-29
ZA201204183B (en) 2013-02-27
US8952179B2 (en) 2015-02-10
GT201200182A (es) 2014-09-18
MD4345B1 (ro) 2015-04-30
EP2532651B1 (fr) 2015-08-05
DK2532651T3 (en) 2015-11-09
US8664408B2 (en) 2014-03-04
MA33883B1 (fr) 2013-01-02
TWI499584B (zh) 2015-09-11
NI201200102A (es) 2012-08-20
US20140100374A1 (en) 2014-04-10
US20140155453A1 (en) 2014-06-05
IL219925A0 (en) 2012-10-31
AR086848A1 (es) 2014-01-29
UY34110A (es) 2013-01-03
PH12012000124A1 (en) 2014-01-20
WO2012168657A1 (fr) 2012-12-13
CO6580197A1 (es) 2012-12-17
AU2012203062B2 (en) 2015-05-07
JP2012254982A (ja) 2012-12-27
EA022741B1 (ru) 2016-02-29
MD20120049A2 (ro) 2012-12-31
SI2532651T1 (sl) 2015-10-30
KR20140079346A (ko) 2014-06-26
HRP20151073T1 (hr) 2015-11-06
RU2013158817A (ru) 2015-07-20
CN102816102A (zh) 2012-12-12
JP2015044840A (ja) 2015-03-12
KR20120136296A (ko) 2012-12-18
TN2012000254A1 (fr) 2013-12-12
ECSP12011941A (es) 2012-07-31
EP2532651A1 (fr) 2012-12-12
GEP20156395B (en) 2015-11-10
CR20120274A (es) 2013-01-11
SG186546A1 (en) 2013-01-30
CA2779045C (fr) 2016-06-21
BR102012013573A2 (pt) 2013-07-02
FR2976285B1 (fr) 2013-05-24

Similar Documents

Publication Publication Date Title
PE20130046A1 (es) Procedimiento de sintesis y forma cristalina hidrocloruro de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida asi como las composiciones farmaceuticas que la contienen
JO2894B1 (en) Salt and new amorphous images
MX2012015252A (es) Estimuladores de sgc.
NZ607794A (en) N-acylsulfonamide apoptosis promoters
MY158339A (en) DIAMIDE COMPOUNDS HAVING MUSCARING RECEPTOR ANTAGONIST AND ß2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
PH12013500745A1 (en) Azaadamantane derivatives and methods of use
IN2012DN01627A (es)
NZ608903A (en) Pesticidal compositions and processes related thereto
TN2013000362A1 (en) Benzodioxane inhibitors of leukotriene production
MX2012013332A (es) Preparacion de intermediarios de posaconazol.
GEP20135882B (en) Crystal form of phenylamino pyrimidine derivatives
AR079932A1 (es) Metodo para la preparacion de nebivolol y compuestos intermediarios.
BRPI0918580A8 (pt) Polimorfo cristalino b da n-(2-aminofenil)-4-[n-(piridina3-il)metóxi-carbonilaminometil]-benzamida, composição e combinação contendo o mesmo, uso e seu processo de produção
MX350862B (es) Acidos de piperidinil naftilacetico.
TN2011000597A1 (en) Non-caking salt composition, preparation process and use thereof
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
IN2012DN05122A (es)
NZ707115A (en) Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds
WO2010107993A3 (en) Process for preparing (r)-7v-benzyl-2- (benyloxycarbonylamino)-s-methoxypropionamide
SG178880A1 (en) Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
MX2015006806A (es) Procedimiento para preparar 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1 -oxido-4-piridil)-5-metoxipiridina-2-carboxamida.
MX2010002300A (es) Polimorfos de sal sodica del acido (3-(((4-terc-butil-bencil)-(pir idin-3-sulfonil)-amino)-metil)-fenoxi)-acetico o un hidrato de los mismos y procedimientos para fabricar los mismos.
TW200708507A (en) A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles
MY157442A (en) Hydrate of sulfonylurea compound, process for producing the same and formulation containing the same
TN2011000091A1 (en) N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b

Legal Events

Date Code Title Description
FC Refusal